Genital Herpes News and Research

RSS

European Medicines Agency awards orphan drug designation to NanoViricides' DengueCide

NanoViricides, Inc. announced today that the European Medicines Agency, has awarded orphan drug designation to DengueCide, the Company's drug candidate for the treatment of dengue and dengue hemorrhagic fever.

11 Nov 2013

Researchers launch clinical trial of investigational vaccine designed to prevent genital herpes disease

Researchers have launched an early-stage clinical trial of an investigational vaccine designed to prevent genital herpes disease. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is sponsoring the Phase I trial, which is being conducted at the NIH Clinical Center in Bethesda, Md.

11 Nov 2013

NanoViricides’ FluCide drug candidate found to be well tolerated in non-GLP safety/toxicology study

NanoViricides, Inc. (the "Company") reports that its optimized injectable FluCide® drug candidate was found to be well tolerated in a non-GLP small animal safety/toxicology study. This study is an important step in the drug development pathway for FluCide.

21 Oct 2013

Most U.S. adolescents lack antibodies that may help protect against genital herpes, says study

A new study suggests a growing number of U.S. adolescents lack antibodies that may help protect them later in life against an increasingly important cause of genital herpes. Published in The Journal of Infectious Diseases and available online, the findings show that fewer of today's teens have been exposed in their childhood to herpes simplex virus type 1 (HSV-1), a common cause of cold sores, than U.S. adolescents in previous years.

17 Oct 2013

Discovery paves way for development of new medicines to combat herpes infections

Researchers at Lund University in Sweden and Carnegie Mellon University have for the first time managed to measure the internal pressure that enables the herpes virus to infect cells in the human body. The discovery paves the way for the development of new medicines to combat viral infections. The results indicate good chances to stop herpes infections in the future.

3 Oct 2013

Researchers potentially reached milestone in vaccine treatment for genital herpes

Sexually transmitted infection researchers potentially have reached a milestone in vaccine treatment for genital herpes, according to a report to be presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy in Denver, Colo., on today, Sept. 12.

13 Sep 2013

Pain, itching associated with shingles may be due to virus causing "short circuit" in nerve cells

The pain and itching associated with shingles and herpes may be due to the virus causing a "short circuit" in the nerve cells that reach the skin, Princeton researchers have found.

11 Sep 2013

Apoptosis can reactivate latent herpesviruses in dying cell

Researchers have found that apoptosis, a natural process of programmed cell death, can reactivate latent herpesviruses in the dying cell. The results of their research, which could have broad clinical significance since many cancer chemotherapies cause apoptosis, was published ahead of print in the Journal of Virology.

6 Sep 2013

NanoViricides, LRRI sign NDA for IND-enabling efficacy studies on FluCide drug candidates

NanoViricides, Inc. said it has signed a non-disclosure agreement with the Lovelace Respiratory Research Institute. The Company intends to enter into a Master Services Agreement with LRRI for the IND-enabling efficacy studies of both its broad-spectrum injectable and oral FluCide drug candidates.

5 Aug 2013

NanoViricides submits letter of intent to file Orphan Drug Application with EMA for DengueCide

NanoViricides, Inc. announced today that it has submitted its letter of intent to file an Orphan Drug Application with the European Medicines Agency for DengueCide, its drug candidate for the treatment of dengue and dengue hemorrhagic fever.

1 Jul 2013

European Commission grants orphan drug designation for maribavir for treatment of CMV disease

ViroPharma Incorporated today announced that the European Commission has granted orphan drug designation for maribavir for treatment of cytomegaloviral disease in patients with impaired cell mediated immunity.

11 Jun 2013

NanoViricides files Orphan Drug application with FDA for DengueCide

NanoViricides, Inc. announced today that it has filed an Orphan Drug application with the Office of Orphan Product Development of the US FDA for DengueCide, its drug candidate for the treatment of dengue and dengue hemorrhagic fever.

10 Jun 2013

Scientists identify new class of immune cells that suppress genital herpes

Fred Hutchinson Cancer Research Center and University of Washington scientists have identified a class of immune cells that reside long-term in the genital skin and mucosa and are believed to be responsible for suppressing recurring outbreaks of genital herpes.

9 May 2013

FDA approves Mylan's ANDA for generic version of Zovirax Ointment

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Acyclovir Ointment USP, 5%.

4 Apr 2013

Viral protein hijacks cellular machinery and grabs the wheel

Northwestern Medicine scientists have identified a component of the herpesvirus that "hijacks" machinery inside human cells, allowing the virus to rapidly and successfully invade the nervous system upon initial exposure.

30 Mar 2013

A new strategy to prevent herpes virus infections

Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered a novel strategy for preventing infections due to the highly common herpes simplex viruses, the microbes responsible for causing genital herpes (herpes simplex virus 2) and cold sores (herpes simplex virus 1).

26 Mar 2013

NanoViricides retires Series C Convertible Preferred Stock previously purchased by Seaside

NanoViricides, Inc., announced today that it has retired the remainder of the Series C Convertible Preferred Stock previously purchased by Seaside 88, LP, with a cash payment.

27 Feb 2013

NanoViricides to advance influenza drug candidate with completed $5M funding

NanoViricides, Inc., announced today that it has received the final tranche of $2.5M from Seaside 88, LP, thereby completing the total of a $5M financing. This raise, and the receipt of the initial $2.5M tranche, was previously announced on June 29, 2012.

25 Dec 2012

NanoViricides’ oral FluCide dramatically improves survival in animals with H3N2 influenza A

NanoViricides, Inc. reported today that its oral FluCide drug candidates demonstrated dramatically improved survival in animals administered a lethal dose of the H3N2 influenza A virus.

24 Sep 2012

Strong antiviral antibody response observed in oral administration of Flucide

NanoViricides, Inc. announced today that anti-influenza drug candidates under its FluCide program, when given orally, led to strong antiviral antibody response. The antibody response with Oral administration was stronger than that with IV administration and was substantially greater than that observed with oseltamivir.

5 Sep 2012